Posted by Michael Wonder on 01 Sep 2020
Emgality is included in the high-cost protection with limitation
1 September 2020 - Emgality (galcanezumab), which is a preventive drug treatment for migraines, is included in the high-cost protection with limited subsidy from 28 August 2020.
The restriction means that the drug is only subsidised for patients with chronic migraine who have not had or have not tolerated at least two different preventive drug treatments.
To ensure that the restriction to patients with chronic migraine is complied with and that the treatment is given to the patients who have the greatest need, TLV believes that the doctors with the most experience of treatment with patients with chronic migraine are the ones who should prescribe galcanezumab with a subsidy.
